Amundi Reduces Holdings in Infosys Limited (NYSE:INFY)

Amundi trimmed its position in shares of Infosys Limited (NYSE:INFY) by 17.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,773,275 shares of the technology company’s stock after selling 363,991 shares during the quarter. Amundi’s holdings in Infosys were worth $40,395,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Assetmark Inc. lifted its position in shares of Infosys by 37.4% during the third quarter. Assetmark Inc. now owns 25,963 shares of the technology company’s stock worth $578,000 after purchasing an additional 7,066 shares during the last quarter. Baillie Gifford & Co. lifted its position in shares of Infosys by 4.6% during the third quarter. Baillie Gifford & Co. now owns 3,089,058 shares of the technology company’s stock worth $68,793,000 after purchasing an additional 135,911 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Infosys by 6,071.1% during the third quarter. Victory Capital Management Inc. now owns 4,739,830 shares of the technology company’s stock worth $105,556,000 after purchasing an additional 4,663,023 shares during the last quarter. Empower Advisory Group LLC lifted its position in shares of Infosys by 23.4% during the third quarter. Empower Advisory Group LLC now owns 20,120 shares of the technology company’s stock worth $448,000 after purchasing an additional 3,820 shares during the last quarter. Finally, D Orazio & Associates Inc. lifted its position in shares of Infosys by 9.1% during the third quarter. D Orazio & Associates Inc. now owns 16,068 shares of the technology company’s stock worth $358,000 after purchasing an additional 1,344 shares during the last quarter. 16.20% of the stock is owned by hedge funds and other institutional investors.

Infosys Trading Down 2.5 %

Shares of NYSE:INFY opened at $18.51 on Thursday. The company has a market capitalization of $76.65 billion, a PE ratio of 23.42, a PEG ratio of 3.50 and a beta of 1.01. The business has a 50 day moving average of $21.42 and a two-hundred day moving average of $22.13. Infosys Limited has a 12-month low of $16.04 and a 12-month high of $23.63.

Infosys (NYSE:INFY) last announced its earnings results on Thursday, January 16th. The technology company reported $0.19 earnings per share for the quarter, hitting the consensus estimate of $0.19. Infosys had a return on equity of 31.60% and a net margin of 17.28%. During the same quarter in the prior year, the business posted $0.18 earnings per share. Equities research analysts predict that Infosys Limited will post 0.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on INFY shares. StockNews.com downgraded Infosys from a “buy” rating to a “hold” rating in a report on Monday. HSBC upgraded Infosys from a “hold” rating to a “buy” rating in a research note on Monday, December 9th. Guggenheim restated a “neutral” rating on shares of Infosys in a research note on Friday, January 17th. Hsbc Global Res upgraded Infosys from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 9th. Finally, CLSA upgraded Infosys from a “hold” rating to an “outperform” rating in a research report on Friday, March 7th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $20.22.

Infosys Profile

Infosys Ltd. is a digital services and consulting company, which engages in the provision of end-to-end business solutions. It operates through the following segments: Financial Services, Retail, Communication, Energy, Utilities, Resources, and Services, Manufacturing, Hi-Tech, Life Sciences, and All Other.